Unknown

Dataset Information

0

Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.


ABSTRACT: Despite considerable efforts to develop medications to treat psychostimulant use disorders, none have proven effective, leaving an underserved patient population and unanswered questions as to what mechanism(s) of action should be targeted for developing pharmacotherapies. Atypical dopamine transporter (DAT) inhibitors, based on (±)modafinil, have shown therapeutic potential in preclinical models of psychostimulant abuse. However, metabolic instability among other limitations to piperazine analogues 1-3 have impeded further development. Herein, bioisosteric substitutions of the piperazine ring were explored with a series of aminopiperidines (A) and piperidine amines (B) wherein compounds with either a terminal tertiary amine or amide were synthesized. Several lead compounds showed high to moderate DAT affinities and metabolic stability in rat liver microsomes. Aminopiperidines 7 (DAT Ki = 50.6 nM), 21b (DAT Ki = 77.2 nM) and 33 (DAT Ki = 30.0 nM) produced only minimal stimulation of ambulatory activity in mice, compared to cocaine, suggesting an atypical DAT inhibitor profile.

SUBMITTER: Giancola JB 

PROVIDER: S-EPMC7680422 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Structure-activity relationships for a series of (Bis(4-fluorophenyl)methyl)sulfinylethyl-aminopiperidines and -piperidine amines at the dopamine transporter: Bioisosteric replacement of the piperazine improves metabolic stability.

Giancola JoLynn B JB   Bonifazi Alessandro A   Cao Jianjing J   Ku Therese T   Haraczy Alexandra J AJ   Lam Jenny J   Rais Rana R   Coggiano Mark A MA   Tanda Gianluigi G   Newman Amy Hauck AH  

European journal of medicinal chemistry 20200809


Despite considerable efforts to develop medications to treat psychostimulant use disorders, none have proven effective, leaving an underserved patient population and unanswered questions as to what mechanism(s) of action should be targeted for developing pharmacotherapies. Atypical dopamine transporter (DAT) inhibitors, based on (±)modafinil, have shown therapeutic potential in preclinical models of psychostimulant abuse. However, metabolic instability among other limitations to piperazine analo  ...[more]

Similar Datasets

| S-EPMC9617638 | biostudies-literature
| S-EPMC10666245 | biostudies-literature
| S-EPMC5746459 | biostudies-literature
| S-EPMC9124866 | biostudies-literature
| S-EPMC7151723 | biostudies-literature
| S-EPMC3150822 | biostudies-literature
| S-EPMC4027546 | biostudies-literature
| S-EPMC10507793 | biostudies-literature
| S-EPMC7698448 | biostudies-literature
| S-EPMC2932959 | biostudies-literature